A single 8-Gy dose of radiotherapy for painful bone metastases may improve quality of life and pain as early as 10 days after administration.
Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.
New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent MetastasesJune 16, 2016
Researchers demonstrate how breast cancer cells invade bone marrow, where they escape chemotherapy and hormonal therapies that would otherwise eliminate the cancer cells.
Men with prostate cancer and bone metastases that have experienced at least one skeletal-related event (SRE) show worse survival, according to a recent study.
Tumor Location and Duration of Therapy Influence Palliative Effects of Radiation Therapy for Painful Bone MetastasesDecember 31, 2015
In a review of the Dutch Bone Metastasis Study results, stratified for primary tumor location, palliative radiation therapy was found to reduce pain and improve quality of life for some patients.
Cancer researchers have identified the molecular pathways that lead to cancer-associated muscle weakness. When they inhibited TGF-β, muscle function improved in mouse models of human cancers.
A new study may have uncovered the key to the early detection of patients at risk of developing metastasis to bone.
A new study is testing a new combination treatment that uses directly applied radiation to ease the pain from cancer that has spread to the spine.
Although prostate cancer can be successfully treated in many men, if the disease metastasizes to the bone, it is eventually lethal.
Resistance training and aerobic exercise programs specifically designed to avoid injuring fragile areas of bone metastases are safe.
For patients with breast cancer, oral bisphosphonates may reduce risk for developing bone metastasesOctober 03, 2014
Oral bisphosphonates to treat osteoporosis may also slow skeletal metastases caused by breast cancer.
The European Journal of Cancer has released a position statement on recent developments in MRI and PET and how these techniques can be used to detect bone metastases.
Single-fraction radiation therapy (SFRT) as effective as multiple-fraction (MFRT) for palliating bone metastasesAugust 15, 2014
Standardizing prescribing practices for single-fraction radiation therapy (SFRT) for palliation of bone metastases could lead to cost savings and improvement in patients' quality of life, according to a new study.
What is the preferred delivery protocol for breast cancer adjuvant bisphosphonates?
Nanomedicine technologies were utilized to develop a drug-delivery system that precisely targets and attacks cancer cells in the bone. It also increases bone strength and volume to prevent bone cancer progression.
In patients with breast cancer who had previously received monthly intravenous bisphosphonate therapy for bone metastases for a year or longer, maintenance zoledronic acid administered every 12 weeks was noninferior to every 4 weeks.
A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients.
Adding dasatinib to the standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer. These results of a phase 2 clinical trial were presented at the 2013 San Antonio Breast Cancer Symposium.
An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones. This study adds long-term survival and safety data for the drug tasquinimod, a new candidate for treating advanced and recurrent prostate cancer.
The epidemiology and pathophysiology of cancer-associated bone disease was reviewed in a new paper published by an International Osteoporosis Foundation (IOF) Committee of Scientific Advisors Working Group.
Despite long-running evidence demonstrating that a single session of radiotherapy provides just as much pain relief to patients with terminal cancer as multiple treatments, the method has yet to be adopted into routine practice.
Management of bone metastasis is an increasingly common challenge. Palliative radiotherapy is proving to effectively relieve pain and improve quality of life for patients.
The monoclonal antibody trastuzumab (Herceptin) may be effective against HER2-negative breast cancers in addition to HER2-positive disease.
New evidence suggests that an otherwise promising class of drugs may actually increase the risk of tumors spreading to bone. The drugs block survival signals that many cancer cells rely on to stay alive; however, targeting the same protein that makes tumors vulnerable to death also overactivates osteoclasts.
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.
Differences in the impact of aspirin in various forms of cancer are highlighted in two studies recently published in the oncology literature.
Denosumab better prevents skeletal complications, ups health-related QoL versus zoledronic acid.
As a patient reveals a difficult past and a wished-for possibility, her nurse ponders the struggle to find the right words to say in a delicate situation.
Several newly approved drugs plus more in the pipeline present the real possibility of prolonging survival in men with advanced prostate cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|